CRNX vs VKTX
CRNX: A commercial-stage endocrine pharmaceutical company with a first-in-class oral GPCR-targeted therapy for acromegaly and a deep pipeline of programs across multiple endocrine diseases. VKTX: Viking is developing VK2735, a novel dual GLP-1/GIP receptor agonist in Phase 3 trials for obesity and metabolic disorders, targeting a high-growth market currently dominated by single-agent GLP-1 therapies.
Side-by-side fundamentals
| Metric | CRNX | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $83.72 | $37.31 | |
| Market cap as of 2026-07-23 | $8.9B | $4.3B | |
| PEG as of 2026-07-23 | -0.47 | -0.04 | CRNX lower |
| Net margin as of 2026-07-23 | -2747.2% | n/a | |
| Gross margin as of 2026-07-23 | +86.0% | n/a | |
| Operating margin as of 2026-07-23 | -3020.3% | n/a | |
| ROE as of 2026-07-23 | -44.0% | -71.3% | CRNX higher |
| ROA as of 2026-07-23 | -39.6% | -65.3% | CRNX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | +2277.5% | n/a | |
| Beta as of 2026-07-23 | 0.11 | 0.65 | |
| 1-year return as of 2026-07-22 close | +171.1% | +16.2% | CRNX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.